The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

The FDA has granted full approval to Precigen’s Papzimeos (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis (RRP). Papzimeos is a non-replicating adenoviral ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Eli Lilly partners with the Indiana Fever and YMCA to empower girls in basketball, removing barriers and promoting community engagement in sports.

Rob Abbott, CEO, ISPOR, highlights how emerging data strategies, advanced technology, and a renewed focus on patient needs are setting the direction for the next era of healthcare worldwide.

Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs ...

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...